Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells

A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer

(2015) Ya-Ting Yang et al.   NEOPLASIA

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells

(2010) Sonja Mandl-Weber et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

The potential role of epigenetic therapy in multiple myeloma

(2009) Emma M. Smith et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

(2009) A. Badros et al.   CLINICAL CANCER RESEARCH

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib

(2009) Richard A. Campbell et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

(2009) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Vorinostat in solid and hematologic malignancies

(2009) David Siegel et al.   Journal of Hematology & Oncology

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models

(2009) S Deleu et al.   LEUKEMIA

OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model

(2008) A. M. Sargeant et al.   CANCER RESEARCH

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

(2008) Enrique M Ocio et al.   LANCET ONCOLOGY

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

(2008) Paul Richardson et al.   LEUKEMIA & LYMPHOMA

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

(2008) Rentian Feng et al.   MOLECULAR CANCER THERAPEUTICS